BioCrine Overview
- Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
7
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$3.33M
- Investors
-
1
BioCrine General Information
Description
Developer of pharmaceutical innovations for the treatment of diabetes. The company's goal is to commercialize new concepts of treatment and enable continual delivery of novel drugs both for diabetes itself and for the complications that the disease induces.
Contact Information
Website
biocrine.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Drug Delivery
Parent Company
Primary Office
- Sveavägen 166
- Box 3073
- 169 03 Solna
- Sweden
+46 072-042 00 00
BioCrine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 26-Sep-2013 | $3.33M | Completed | Startup | ||
| 2. Merger/Acquisition | 29-Apr-2002 | Completed | Startup | |||
| 1. Early Stage VC | Completed | Startup |
BioCrine Patents
BioCrine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200023013-A1 | Methods and reagents for treating diabetes | Pending | 19-Jul-2018 | 00000000 | |
| EP-3823648-A1 | Methods and reagents for treating diabetes | Pending | 19-Jul-2018 | 00000000 | |
| JP-2021530476-A | Methods and reagents for treating diabetes | Active | 19-Jul-2018 | 00000000 | |
| US-9968675-B2 | Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis | Inactive | 09-Feb-2015 | 00000000000 | |
| EP-3256118-A1 | Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis | Inactive | 09-Feb-2015 | A61K45/06 |
BioCrine Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Per-Olof Berggren Ph.D | Founder, Chief Executive Officer & Board Member | ||
| Catharina Rahm | Chief Financial Officer |
BioCrine Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Claes-Henrik Julander | Self | Board Member | 000 0000 |
| Gunnar Olsson Ph.D | Self | Board Member | 000 0000 |
| Kenth Petersson | Self | Chairman | 000 0000 |
| Martin Nicklasson Ph.D | Self | Board Member | 000 0000 |
| Per-Olof Berggren Ph.D | BioCrine | Founder, Chief Executive Officer & Board Member | 000 0000 |
BioCrine Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BioCrine Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| HealthCap | Venture Capital | Minority | 000 0000 | 000000 0 |